{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:39:18Z","timestamp":1784907558523,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.rmed.2025.108223","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T02:28:10Z","timestamp":1750904890000},"page":"108223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world respiratory effectiveness of mepolizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis"],"prefix":"10.1016","volume":"246","author":[{"given":"Wenjiao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhui","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6532-3191","authenticated-orcid":false,"given":"Meiling","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rmed.2025.108223_bib1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.rmed.2025.108223_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/1744666X.2019.1697678","article-title":"Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease","volume":"16","author":"Berti","year":"2020","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2025.108223_bib3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaip.2015.12.014","article-title":"Asthma control and airway inflammation in patients with eosinophilic granulomatosis with polyangiitis","volume":"4","author":"Latorre","year":"2016","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"5","key":"10.1016\/j.rmed.2025.108223_bib4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1183\/13993003.00097-2016","article-title":"Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"48","author":"Cottin","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108223_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/JAA.S461800","article-title":"Benralizumab reduces respiratory exacerbations and oral glucocorticosteroid dose in patients with severe asthma and eosinophilic granulomatosis with polyangiitis","volume":"17","author":"M\u00fcmmler","year":"2024","journal-title":"J. Asthma Allergy"},{"issue":"2","key":"10.1016\/j.rmed.2025.108223_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108223_bib7","series-title":"Severe Eosinophilic Asthma in Chinese C\u2010BIOPRED Asthma Cohort, Clinical and Translational Medicine","volume":"vol. 12","author":"Zhang","year":"2022"},{"issue":"4","key":"10.1016\/j.rmed.2025.108223_bib8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the international severe asthma registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.rmed.2025.108223_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CM9.0000000000002556","article-title":"Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies","volume":"136","author":"Deng","year":"2023","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"10.1016\/j.rmed.2025.108223_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaip.2024.10.013","article-title":"Characteristics of severe asthma clinic patients with eosinophilic granulomatosis with polyangiitis","volume":"13","author":"Puan","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.108223_bib11","article-title":"Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases","volume":"14","author":"Del Pozo","year":"2023","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.rmed.2025.108223_bib12","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1016\/j.jaip.2024.08.011","article-title":"Severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis: potential biomarkers for novel diagnostic strategies","volume":"12","author":"Latorre","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.rmed.2025.108223_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"20","key":"10.1016\/j.rmed.2025.108223_bib14","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108223_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"issue":"9842","key":"10.1016\/j.rmed.2025.108223_bib16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.rmed.2025.108223_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02983-2021","article-title":"Cumulative corticosteroid-sparing effect of anti-interleukin-5\/5Ra in eosinophilic asthma","volume":"60","author":"Kroes","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"10209","key":"10.1016\/j.rmed.2025.108223_bib18","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.rmed.2025.108223_bib19","first-page":"576","article-title":"Mepolizumab in CRSwNP\/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia","volume":"62","author":"Fujieda","year":"2024","journal-title":"Rhinology"},{"issue":"9842","key":"10.1016\/j.rmed.2025.108223_bib20","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.rmed.2025.108223_bib21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108223_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1341310","article-title":"Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis","volume":"11","author":"Desaintjean","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.rmed.2025.108223_bib23","article-title":"A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT)","volume":"vol. 19","author":"Cheng","year":"2025"},{"key":"10.1016\/j.rmed.2025.108223_bib24","series-title":"Global Strategy for Asthma Management and Prevention","year":"2021"},{"issue":"8","key":"10.1016\/j.rmed.2025.108223_bib25","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The American college of rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.rmed.2025.108223_bib26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108223_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1034\/j.1399-3003.1999.14a08.x","article-title":"Development and validation of the mini asthma quality of life questionnaire","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.rmed.2025.108223_bib28","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/lary.25108","article-title":"Using preoperative SNOT-22 score to inform patient decision for endoscopic sinus surgery","volume":"125","author":"Rudmik","year":"2015","journal-title":"Laryngoscope"},{"issue":"12","key":"10.1016\/j.rmed.2025.108223_bib29","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.rmed.2025.108223_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00750-2023","article-title":"Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Chen","year":"2024","journal-title":"ERJ open research"},{"key":"10.1016\/j.rmed.2025.108223_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221115054","article-title":"Short-acting beta-2 agonist prescription patterns and clinical outcomes in Chinese patients with asthma: an observational study in mainland China for the SABINA programme","volume":"16","author":"Bao","year":"2022","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"3","key":"10.1016\/j.rmed.2025.108223_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.anai.2024.11.004","article-title":"Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States","volume":"134","author":"Mathur","year":"2025","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"13","key":"10.1016\/j.rmed.2025.108223_bib33","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108223_bib34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108223_bib35","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"15","key":"10.1016\/j.rmed.2025.108223_bib36","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.rmed.2025.108223_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/JAA.S236609","article-title":"Real-World effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs&lt","volume":"13","author":"Llanos","year":"2020","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmed.2025.108223_bib38","article-title":"Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: a real-world database study in Japan, pulmonary","volume":"75","author":"Nagase","year":"2022","journal-title":"Pharmacol. Therapeut."},{"issue":"10","key":"10.1016\/j.rmed.2025.108223_bib39","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: Real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"3","key":"10.1016\/j.rmed.2025.108223_bib40","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.anai.2021.05.021","article-title":"Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities","volume":"127","author":"Casale","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2025.108223_bib41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-World effectiveness and the characteristics of a \"Super-Responder\" to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rmed.2025.108223_bib42","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/02770903.2020.1723623","article-title":"Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety","volume":"58","author":"van Toor","year":"2021","journal-title":"J. Asthma"},{"issue":"4","key":"10.1016\/j.rmed.2025.108223_bib43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.23822\/EurAnnACI.1764-1489.289","article-title":"A real-life cohort of mepolizumab treatment in severe eosinophilic asthma","volume":"56","author":"Laorden","year":"2024","journal-title":"Eur. ann. allergy clin. immunol."},{"issue":"10","key":"10.1016\/j.rmed.2025.108223_bib44","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108223_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1204444","article-title":"Effectiveness and safety of anti-IL-5\/Ralpha biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study","volume":"14","author":"Nolasco","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.rmed.2025.108223_bib46","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/j.clinthera.2021.03.023","article-title":"Real-world effectiveness of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis","volume":"43","author":"Li","year":"2021","journal-title":"Clin. Ther."},{"issue":"10","key":"10.1016\/j.rmed.2025.108223_bib47","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125002860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125002860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:06:29Z","timestamp":1754258789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125002860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":47,"alternative-id":["S0954611125002860"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108223","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world respiratory effectiveness of mepolizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108223"}}